PDF(Pubmed)
Abstract：
UNASSIGNED: Negative symptoms, frequently experienced by people with schizophrenia, can impair functional outcomes and quality of life. Negative symptoms typically affect motivation, communication, and the ability to live independently and are difficult to treat. Several meta-analyses suggest that cognitive behavioural therapy results in a modest reduction in negative symptoms. It is unclear if similar effects can be achieved using behavioural activation. Behavioural activation is a derivative of cognitive behavioural therapy that helps to improve social and emotional functioning by encouraging patients to engage in activities that they value whilst modifying the avoidance responses. Behavioural activation can be a standalone treatment for depressive symptoms that is equally as efficacious as cognitive behavioural therapy.
UNASSIGNED: This systematic review aimed to identify and summarise the evidence about the efficacy of behavioural activation in treating negative symptoms.
UNASSIGNED: Systematic review.
UNASSIGNED: Two published studies conducted in South Korea and the United Kingdom recruited 55 patients.
UNASSIGNED: We searched five databases and four trial registries for clinical treatment trials of behavioural activation involving adults diagnosed with negative symptoms of schizophrenia. Studies were screened according to the inclusion criteria and assessed for quality.
UNASSIGNED: We identified 5023 published studies. After removing duplicates and conducting screening, two studies were included in this review. One study used a parallel non-randomised trial design whilst the other adopted a single group test-re-test design. Fifty-five participants were recruited from hospital and community settings. Both studies delivered 10 face-to-face sessions of behavioural activation; these were individual in one study and group sessions in the other. One study involved behavioural activation as the treatment whilst the other delivered behavioural activation with motivational interviewing. Neither study reported harms or adverse events.
UNASSIGNED: Based on the included studies, there is low-quality evidence that behavioural activation may be helpful in the treatment of negative symptoms. Key limitations of the studies include small sample sizes and overall low study quality.
UNASSIGNED: The protocol covering this review was registered with Open Science on 18 February 2022 (Registration DOI 10.17605/OSF.IO/57QSW; Weblink: https://osf.io/57qsw).
UNASSIGNED: Behavioural activation holds promise in supporting patients experiencing negative symptoms of schizophrenia.
UNASSIGNED: This systematic review aimed to identify and summarise the evidence about the efficacy of behavioural activation in treating negative symptoms.
UNASSIGNED: Systematic review.
UNASSIGNED: Two published studies conducted in South Korea and the United Kingdom recruited 55 patients.
UNASSIGNED: We searched five databases and four trial registries for clinical treatment trials of behavioural activation involving adults diagnosed with negative symptoms of schizophrenia. Studies were screened according to the inclusion criteria and assessed for quality.
UNASSIGNED: We identified 5023 published studies. After removing duplicates and conducting screening, two studies were included in this review. One study used a parallel non-randomised trial design whilst the other adopted a single group test-re-test design. Fifty-five participants were recruited from hospital and community settings. Both studies delivered 10 face-to-face sessions of behavioural activation; these were individual in one study and group sessions in the other. One study involved behavioural activation as the treatment whilst the other delivered behavioural activation with motivational interviewing. Neither study reported harms or adverse events.
UNASSIGNED: Based on the included studies, there is low-quality evidence that behavioural activation may be helpful in the treatment of negative symptoms. Key limitations of the studies include small sample sizes and overall low study quality.
UNASSIGNED: The protocol covering this review was registered with Open Science on 18 February 2022 (Registration DOI 10.17605/OSF.IO/57QSW; Weblink: https://osf.io/57qsw).
UNASSIGNED: Behavioural activation holds promise in supporting patients experiencing negative symptoms of schizophrenia.
摘要：
■阴性症状，精神分裂症患者经常经历，会损害功能结果和生活质量。负面症状通常会影响动机，通信,以及独立生活和难以治疗的能力。一些荟萃分析表明，认知行为疗法可适度减少阴性症状。目前尚不清楚使用行为激活是否可以实现类似的效果。行为激活是认知行为疗法的衍生物，通过鼓励患者参与他们重视的活动，同时修改回避反应，有助于改善社交和情感功能。行为激活可以是抑郁症状的独立治疗，与认知行为治疗一样有效。
■本系统综述旨在确定和总结有关行为激活治疗阴性症状的有效性的证据。
■系统评价。
■在韩国和英国进行的两项已发表的研究招募了55名患者。
■我们检索了五个数据库和四个试验登记处，寻找行为激活的临床治疗试验，这些试验涉及被诊断为精神分裂症阴性症状的成年人。根据纳入标准筛选研究并进行质量评估。
■我们确定了5023项已发表的研究。删除重复项并进行筛选后，本综述包括两项研究.一项研究使用平行非随机试验设计，而另一项研究采用单组测试-再测试设计。从医院和社区环境中招募了55名参与者。两项研究都进行了10次面对面的行为激活会议；这些是一项研究中的个人会议，另一项研究中的小组会议。一项研究涉及行为激活作为治疗，而另一项研究通过动机性访谈提供行为激活。两项研究均未报告危害或不良事件。
■根据纳入的研究，有低质量的证据表明,行为激活可能有助于治疗阴性症状.研究的主要局限性包括样本量小和总体研究质量低。
■涵盖此审查的协议于2022年2月18日在OpenScience注册（注册DOI10.17605/OSF。IO/57QSW;Weblink:https://osf.io/57qsw)。
■行为激活在支持患有精神分裂症阴性症状的患者方面具有希望。
■本系统综述旨在确定和总结有关行为激活治疗阴性症状的有效性的证据。
■系统评价。
■在韩国和英国进行的两项已发表的研究招募了55名患者。
■我们检索了五个数据库和四个试验登记处，寻找行为激活的临床治疗试验，这些试验涉及被诊断为精神分裂症阴性症状的成年人。根据纳入标准筛选研究并进行质量评估。
■我们确定了5023项已发表的研究。删除重复项并进行筛选后，本综述包括两项研究.一项研究使用平行非随机试验设计，而另一项研究采用单组测试-再测试设计。从医院和社区环境中招募了55名参与者。两项研究都进行了10次面对面的行为激活会议；这些是一项研究中的个人会议，另一项研究中的小组会议。一项研究涉及行为激活作为治疗，而另一项研究通过动机性访谈提供行为激活。两项研究均未报告危害或不良事件。
■根据纳入的研究，有低质量的证据表明,行为激活可能有助于治疗阴性症状.研究的主要局限性包括样本量小和总体研究质量低。
■涵盖此审查的协议于2022年2月18日在OpenScience注册（注册DOI10.17605/OSF。IO/57QSW;Weblink:https://osf.io/57qsw)。
■行为激活在支持患有精神分裂症阴性症状的患者方面具有希望。
